Taiwan FDA registration e4a5e384f8de0df945fd8ce1eb61f4a1
Baijie uric acid test tablets (unsterilized)
TW: 百捷尿酸試片 (未滅菌)
Taiwan·Risk Class 1·Qinli Biotechnology Co., Ltd. New North Plant·Registered Apr 11, 2022 – Apr 11, 2027ActiveRegistration details
- Analysis ID
- e4a5e384f8de0df945fd8ce1eb61f4a1
Company information
- Manufacturer
- Qinli Biotechnology Co., Ltd. New North Plant
- Manufacturer Country
- Taiwan, Province of China
- Authorized Representative
- GENERAL LIFE BIOTECHNOLOGY CO., LTD.
Product details
- Intended Use
- Limited to the first level identification scope of the "uric acid test system (A.1775)" of the Measures for the Classification and Grading Management of Medical Devices.
- Product Type (Level 1)
- A Clinical chemistry and clinical toxicology
- Product Type (Level 2)
- A.1775 尿酸試驗系統
- Import Information
- 國產;; QMS/QSD
Dates and status
- Registration Date
- Apr 11, 2022
- Expiry Date
- Apr 11, 2027
About this record
Access comprehensive regulatory information for Baijie uric acid test tablets (unsterilized) in Taiwan's medical device market through Pure Global AI's free database. This Risk Class 1 medical device is registered under number e4a5e384f8de0df945fd8ce1eb61f4a1 and manufactured by Qinli Biotechnology Co., Ltd. New North Plant. The authorized representative in Taiwan is GENERAL LIFE BIOTECHNOLOGY CO., LTD..
This page provides complete technical specifications, regulatory compliance details. Pure Global AI offers free access to 89,000+ Taiwan medical device registrations, helping global MedTech companies navigate Taiwan FDA regulations, identify competitors, and discover partnership opportunities efficiently.
Free DatabasePowered by Pure Global AI89,000+ Devices